Highlights

  • Mesoblast (ASX:MSB) reported September-quarter Ryoncil net revenue of US$28 million, up 44% year on year.
  • Preliminary September-quarter net operating cash spend decreased to US$2.3 million from US$14.9 million.
  • FY26 total revenue was US$120.3 million, compared with US$17.2 million in FY25.
  • The company completed treatment of 350 patients in its Phase 3 chronic low back pain trial.

Mesoblast Limited (ASX:MSB) develops and commercialises allogeneic cell therapies for inflammatory diseases, with Ryoncil forming the centre of its current US commercial operations. In mid-October, the company released preliminary sales and operating cash figures for the three months ended 30 September 2026. At the time of writing this article on 19 October 2026, Mesoblast shares were trading at AUD 1.80, down 9.80% during the day’s trading session. The recent disclosure follows FY26 results and updates on the company’s clinical development programmes.

Company Business

Mesoblast develops medicines derived from donor-sourced mesenchymal lineage cells, designed to address inflammatory and immune-mediated conditions. Its first US-approved product, Ryoncil (remestemcel-L-rknd), treats steroid-refractory acute graft-versus-host disease in paediatric patients aged two months and older. The company also studies remestemcel-L for additional inflammatory indications and rexlemestrocel-L for chronic low back pain and heart failure-related applications. Its operations span Australia, the United States and Singapore, with commercial partnerships in Japan, Europe and China.

Ryoncil commercialisation involves transplant treatment centres, patient identification, reimbursement arrangements, manufacturing and distribution. Cell therapy production requires specialised processes and regulatory quality controls, creating a different operating model from conventional small-molecule medicines.

Recent Development

In October 2026, Mesoblast said Ryoncil generated US$28 million in net sales during the September quarter, compared with US$19 million a year earlier. Management also reported US$2.3 million of net operating cash spend, versus US$14.9 million in the corresponding period, and a cash balance of US$99 million at 30 September. These figures were described as preliminary and remained subject to the usual closing and audit procedures.

The company said September recorded its highest monthly number of new patient starts, following treatment scheduling patterns during July and August. It referred to 54 onboarded treatment sites as part of its commercial adoption programme. Separately, a September announcement confirmed US regulatory approval of a new potency assay for commercial Ryoncil, a manufacturing and quality-related development.

Financial Performance and Sector Context

For the financial year ended 30 June 2026, Mesoblast reported total revenue of US$120.3 million, up from US$17.2 million in FY25. Ryoncil contributed US$115.2 million in net product sales, while reported gross profit reached US$103.6 million. The company recorded a US$57.5 million net loss, compared with US$102.1 million in the previous year, despite higher sales and development activity.

FY26 net operating cash spend was US$43.8 million, against US$50.0 million in FY25. Cash and cash equivalents totalled approximately US$103 million at the end of June, compared with US$161.6 million a year earlier. Mesoblast also established a US$125 million five-year credit-line facility, replacing two higher-cost facilities. These figures indicate the importance of both product receipts and expenditure management as the business funds manufacturing and trials.

The cell therapy sector depends on regulatory oversight, treatment-centre uptake and reimbursement access. Mesoblast said its commercial reimbursement coverage extended to more than 280 million covered lives as of its FY26 update, although coverage does not guarantee treatment volumes or revenue.

Risks to Consider

Ryoncil revenue depends on adoption by specialist treatment centres, eligible patient numbers, reimbursement arrangements and consistent product supply. Commercial manufacturing carries quality, scale-up and compliance requirements. Development candidates face clinical outcome and regulatory review risks; timelines and expenditure may change as studies progress. The company remained loss-making in FY26, while trial spending and debt servicing create continuing demands on liquidity.

What to Watch Next

Key monitoring points include later quarterly Ryoncil sales, patient starts across onboarded sites, operating cash movements and the audited reconciliation of preliminary September-quarter figures. Mesoblast has completed treatment in its 350-patient Phase 3 rexlemestrocel-L trial for chronic low back pain, with top-line findings expected in mid-calendar 2027 following 12-month follow-up. Regulatory and clinical progress for potential adult Ryoncil indications also remains relevant.

Key Insights

Mesoblast enters FY27 with a full year of US Ryoncil commercial sales reflected in its FY26 accounts and additional September-quarter sales disclosed. Revenue increased materially while the reported annual loss narrowed, although the company continues to fund research and clinical programmes. Future reporting will clarify whether quarterly commercial receipts, manufacturing costs and clinical spending remain aligned with the company’s available financial resources.